- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- Precigen Reports First Quarter 2024 Financial Results and Business Updates
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
- Precigen Reports Full Year 2023 Financial Results and Business Updates
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
More ▼
Key statistics
On Thursday, Precigen Inc (PGEN:NSQ) closed at 1.34, 60.40% above the 52 week low of 0.8354 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.40 |
---|---|
High | 1.41 |
Low | 1.33 |
Bid | 1.35 |
Offer | 1.36 |
Previous close | 1.38 |
Average volume | 721.94k |
---|---|
Shares outstanding | 252.42m |
Free float | 223.41m |
P/E (TTM) | -- |
Market cap | 348.34m USD |
EPS (TTM) | -0.3896 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼